Advanced Filters
noise

Vomiting Clinical Trials

A listing of Vomiting medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 660 clinical trials
S Soeren Schou Olesen, PhD

Fibro-inflammatory Progression From Acute to Chronic Pancreatitis

Observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.

18 - 70 years of age All Phase N/A
F Feng Wang

99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled …

18 - 75 years of age All Phase N/A

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related …

19 years of age All Phase N/A
F Feng Wang

18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis

Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.

18 - 75 years of age All Phase N/A
K Kaixuan Wang, MD

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and …

18 years of age All Phase N/A
J Jesse West

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

18 years of age All Phase N/A
y yang hong, MD

MRE for Diagnosis of Pancreatic Masses

Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. The extracellular matrix (ECM) surrounding PDAC …

18 - 80 years of age All Phase N/A
G Guido Costamagna, MD, Prof.

Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherapeutic agents, making this a lethal disease. The investigators hypothesize that: (i) dissection of genetic, stromal, and immunological factors on endoscopic ultrasound fine needle …

18 - 80 years of age All Phase N/A

Collection of Circulating Biomarkers in Pancreatic Cancer

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

18 years of age All Phase N/A
A Anna Dodd

Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial

This is a prospective, multi-centre, translational and observational study. Two cohorts of patients with pancreatic ductal adenocarcinoma (PDAC) are eligible to enroll 1) Upfront resectable PDAC 2) Advanced (unresectable PDAC or metastatic). Patients will have tissue either at resection or from a biopsy at enrolment processed for whole genome sequencing, …

18 years of age All Phase N/A

Simplify language using AI